The recent and upcoming expiration of patents on several blockbuster drugs and resulting loss of revenue will require pharmaceutical companies to search for new means to grow revenues. Megamergers, which were common in the past, will still occur. However, recent acquisitions by many pharmaceutical firms show a move instead to specialize in specific markets. For […]
Earlier this month, the World Steel Association released its “Short Range Outlook” for apparent steel use (ASU) for 2014 and 2015. In 2013, ASU reached 1,481 megatons, an increase of 3.6%. ASU is forecast to grow 3.1% in 2014 and 3.3% in 2015. In 2013, developing economies’ ASU was almost triple that of developed economies, […]
A working group of experts assembled by the US National Human Genome Research Institute has published guidelines for studying how variations in genetic sequence may cause disease in humans. Not all variations play a role in disease, and incorrect assessment of variants can have adverse effects, including incorrect treatments for patients. The guidelines apply to […]
R&D spending, both domestic and abroad, by Pharmaceutical Research and Manufacturers of America (PhRMA) firms in 2013 totaled $51,060 million, up 3.0% compared to a gain of 1.9% in 2012. In 2013, members increased domestic spending 6.9%, a change from 3.1% in 2012, to comprise 79% of total R&D. Spending abroad fell 9.1%, compared to […]
The US’s Protecting Access to Medicare Act of 2014 became law this month and shifts the determination of Medicare payments for clinical lab tests to a market-based system. Starting in January 2017, the Centers for Medicare & Medicaid Services (CMS) will set the Medicare payment rates for clinical lab tests by using the weighted median […]
As a step toward combating global warming, the Obama Administration has released its strategy to reduce methane-emissions in the US. The Administration’s goal is for emissions to be cut by 2020 to 17% below 2005 levels. The methane-reduction strategy for oil and gas production includes updating standards for public lands and supporting technologies for detecting […]
Chemical companies in the US and Europe plan to increase their research and capital spending in 2014, according to a survey conducted by Chemical and Engineering News (C&EN). This year will mark the fifth year of capital spending increases for 20 major chemical firms. Their total projected expenditures for facilities and equipment in 2014 is […]
A report submitted to the US Congress by the Office of Science and Technology Policy details spending on R&D infrastructure. In 2013, $1,710 million was spent on construction of nondefense facilities and capital equipment. A 37.4% increase is estimated for 2014 spending for a total of $2,350 million. However, infrastructure spending for the NIH is […]
Funding for R&D is undergoing a shift in the US, with an increasing trend toward private backing. While federal funds still provide most of the support for the sciences, budget cuts have placed financial strain on some research institutes and programs. According to one study of the 50 universities with the highest budgets for science […]
US President Obama has submitted his 2015 budget request, totaling $3.9 trillion, to Congress. Agencies funding scientific research did not fare well, with increases insufficient to offset inflation in most cases. The requested $30.4 billion budget for the NIH’s is only a 0.7% increase. However, the NIH’s spending for the BRAIN initiative (see IBO 4/15/13) […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
